Future directions in research

Journal of Emergency Medicine

Volumn 27, Issue 4 SUPPL., 2004, Pages

  Currier, Glenn W ^a,b   Allen, Michael H ^c   Bunney, E Bradshaw ^d   Daniel, David G ^e   Francis, Andrew ^f   Jagoda, Andy ^g   Zimbroff, Dan ^h  

^a Department of Psychiatry ^*

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO HOSPITAL   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

^e Bioniche Development Inc   (United States)

^f STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h Pacific Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; ZIPRASIDONE;

AGITATION; CLINICAL EXAMINATION; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; EMERGENCY WARD; HUMAN; INFORMED CONSENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SHORT SURVEY;

EID: 7044225949     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2004.09.005     Document Type: Article

References (9)

1. Klotz SG, Preval H, Southard R, Francis A. Injectable ziprasidone in the psychiatric emergency service. Poster presented at: 156th Annual Meeting of the American Psychiatric Association, May 17-22, 2003, San Francisco, CA.
2. Eli Lilly and Company Zyprexa powder for solution for injection. Summary of product characteristics, 2001 http://www.lilly.co.uk/pdf/ zyprexa%20intramuscular.pdf Accessed September 1, 2003
3. S. Brook, J.V. Lucey, K.P. Gunn Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group J Clin Psychiatry 61 2000 933 941
4. P. Wright, K. Meehan, M Birkett A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy Clin Ther 25 2003 1420 1428
5. Federal Drug Administration Information sheets: Guidance for institutional review boards and clinical investigators 1998 update http://www.fda.gov/oc/ohrt/irbs/ Accessed August 29, 2003
6. J.D. Corrigan Development of a scale for assessment of agitation following traumatic brain injury J Clin Exp Neuropsychol 11 1989 261 277
7. J. Battaglia, S.R. Lindborg, K. Alaka, K. Meehan, P. Wright Calming versus sedative effects of intramuscular olanzapine in agitated patients Am J Emerg Med 21 2003 192 198
8. R.H. Swift, E.P. Harrigan, J.C. Cappelleri, D. Kramer, L.P. Chandler Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients J Psychiatr Res 36 2002 87 95
9. G.W. Currier, J.C.Y. Chou, D Feifel Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam J Clin Psychiatry 65 2004 386 394